RedChip (@RedChip) header
RedChip (@RedChip) profile picture

The World Leader in Small-Cap Investor Relations. This is not investment advice. Full disclosures: https://teapawt.org/t.co/A2Fge25eX2

Orlando, Florida
Joined March 2009
Photo by RedChip (@RedChip)Photo by RedChip (@RedChip)Photo by RedChip (@RedChip)Photo by RedChip (@RedChip)Photo by RedChip (@RedChip)Photo by RedChip (@RedChip)Photo by RedChip (@RedChip)Photo by RedChip (@RedChip)Photo by RedChip (@RedChip)Photo by RedChip (@RedChip)
⏳ Starting in 30 Minutes: FibroBiologics (NASDAQ: FBLG) Live Investor Webinar at 4:15 PM ET Last chance to register. In 30 minutes, FibroBiologics management goes live to discuss how the company is turning the body’s most common connective tissue cell into therapies for chronic disease. Join now to hear the strategy firsthand and get your questions answered live. ⚡ Why you should be in the room: More than 270 patents issued and pending Fibroblasts are abundant, easy to grow and naturally drawn to tumors and injured tissue Disc disease spheroids that preserved disc height better than any other fibroblast approach tested A newly granted European patent for tumor-targeting fibroblast delivery A pipeline spanning multiple chronic disease indications Register now and join us live at 4:15 PM ET. 🔗 Register here: redchip.news/4fchsh2 #FBLG #FibroBiologics #CellTherapy #Fibroblasts #RegenerativeMedicine #WoundHealing #Biotech #NasdaqStocks #InvestorWebinar #SmallCapInvesting
135
🚨 TODAY: FibroBiologics (NASDAQ: FBLG) Live Investor Webinar at 4:15 PM ET The FibroBiologics investor webinar is today. This afternoon, management will present a cell therapy platform built on fibroblasts, with programs across chronic disease, regenerative medicine and cancer. Bring your questions on the pipeline, the patent portfolio and upcoming milestones. 📋 What’s on the table today: A clinical-stage platform using fibroblasts and fibroblast-derived materials More than 270 U.S. and international patents issued and pending Preclinical disc disease data showing an 80.7% disc height index versus 71.8% in controls at 12 weeks A European patent covering fibroblasts that carry oncolytic viruses into tumors Programs spanning wound healing, multiple sclerosis, disc degeneration, psoriasis, orthopedics, longevity and cancer Register now to join the live presentation this afternoon. 🔗 Register here: redchip.news/4fchsh2 #FBLG #FibroBiologics #CellTherapy #Fibroblasts #RegenerativeMedicine #WoundHealing #Biotech #NasdaqStocks #InvestorWebinar #SmallCapInvesting
128
In the first half of 2026, edgeTI (OTCQB: $UNFYF) reported revenue of approximately 3.7 million, up 211% from a year earlier. CEO Jason Nichols says the Australian acquisition from Austal contributed substantially, while U.S. operations grew 38%. The goal now is to grow revenue while improving efficiency and cash performance. Progress will be measured by pipeline, signed programs, successful delivery and better financial results. Watch the full interview with edgeTI CEO Jason Nichols at redchip.news/4t7bHXZ, and join the RedChip Nation to discover more companies like edgeTI. $UNFYF #edgeTI #DefenseTech #SmallCaps #CEOInterview #RedChip
155
A historic milestone for First Phosphate (Nasdaq: $PHOS). UK Export Finance has issued a letter of interest for up to C$220 million in export credit support for the company’s Bégin-Lamarche phosphate mine in Quebec. It joins Denmark and Switzerland, bringing proposed government-backed financing to about US$567.5 million. That exceeds the mine’s estimated US$475 million construction CAPEX, before the feasibility study is even released. On top of that, First Phosphate has C$21.5 million in non-repayable Canadian government contributions and offtake support from Italian export credit and development finance agencies. Lining up this much financing this early is rare for a critical minerals developer, and it puts First Phosphate well ahead in building a North American supply chain for LFP batteries. Learn more: redchip.news/4C7w5fy #FirstPhosphate #PHOS #CriticalMinerals #LFP #BatteryStorage #Phosphate #Mining #ExportFinance #SmallCapStocks #RedChip
1
160
Vector Science and Therapeutics (TSXV: $PAIN): Andrews Research & Education Foundation Partners with Vector to Develop Peptides for Sports and Regenerative Medicine Vector Science and Therapeutics (TSXV: PAIN) announced a collaboration with the Andrews Research & Education Foundation, founded by renowned sports medicine surgeon Dr. James Andrews. Together they will design clinical programs testing Vector’s pharma-grade peptides for soft tissue repair, muscle regeneration in aging athletes and osteoarthritis. Vector will manufacture and supply the peptides, any new intellectual property will be jointly owned, and Vector will lead commercialization through its direct-to-physician sales model. The partners will also build peptide education programs for physicians through the foundation’s sports medicine network. Dr. Andrews and Vector Chairman Tommy Thompson will host a livestreamed briefing today at 11:00 a.m. CST (12:00 p.m. ET). Full press release: redchip.news/48ZG60X
157
Foremost Clean Energy (Nasdaq: $FMST): New Uranium Discovery at Turkey Lake Adds a Second Target Area Alongside Hatchet Lake Foremost Clean Energy (Nasdaq: FMST) discovered uranium in its first-ever drill program at the Turkey Lake project in Saskatchewan’s Athabasca Basin. Hole TL-26-02 returned 0.13% eU₃O₈ over 3.0 metres, including 0.29% over 0.5 metres. What matters most for investors is the location. The discovery sits outside the area historical drilling focused on, which could point to an entirely new mineralized trend on the property. Several similar untested targets remain nearby. Combined with the high-grade discovery at Hatchet Lake, Foremost now has two areas worth follow-up drilling. The next catalyst is chemical assay results, which are pending. Full press release: redchip.news/4zsxAT2
148
Bimergen Energy (NYSE American: $BESS) posted its second straight profitable quarter. Q3 net income rose 50% from Q2 to $2.4 million, on revenue of $3.0 million. The company sold stakes in three Texas battery storage projects while keeping 7.5% of each for long-term upside. With about 2.0 GW across 33 projects still in development, Bimergen sees more opportunities to turn its pipeline into revenue. Full press release: redchip.news/4C94omD #Bimergen #BESS #BatteryStorage #EnergyStorage #CleanEnergy #GridReliability #SmallCapStocks #RedChip
141
Greenwich LifeSciences (Nasdaq: $GLSI): Phase III Breast Cancer Immunotherapy Trial to Be Featured at Major Oncology Conference December 9 Greenwich LifeSciences (Nasdaq: GLSI) will present two posters on its Phase III FLAMINGO-01 trial at the San Antonio Breast Cancer Symposium on December 9. The global trial is evaluating GLSI-100, an FDA Fast Track-designated immunotherapy designed to prevent breast cancer recurrence following surgery. Earlier Phase II results showed no recurrences among fully immunized patients, providing the foundation for the Phase III program, which had expanded to more than 170 clinical sites across the U.S. and Europe as of July 2026. The upcoming presentations will put the program before leading oncology researchers at a conference expected to attract approximately 10,000 healthcare professionals. Both posters are authored by the trial's Steering Committee, with additional details expected during the conference. Full press release: redchip.news/3WMpCqi
2
357
⏰ One Week Away: Nord Precious Metals (OTCQB: $NPMMF, TSXV: NTH) Live Investor Webinar, Tuesday, November 24 at 4:15 PM ET The Nord webinar is one week away. Most junior miners have to discover, define and develop a deposit before they can generate revenue. Nord already controls silver in historic tailings at surface, along with existing processing infrastructure, giving it a potentially faster and less capital-intensive route to production. 📈 What’s driving the story: Historic tailings at surface offer a potentially lower-cost, faster path to production than conventional mine development Nord operates TTL Laboratories, the Cobalt Camp’s only permitted high-grade milling facility It owns a 600-tonne-per-day modular gravity plant intended for tailings recovery Future production cash flow could help fund exploration and reduce reliance on equity financing Upcoming catalysts include permitting, metallurgical studies, project economics and plant commissioning Secure your seat today to hear management’s view of the road ahead. 🔗 Register here: redchip.news/4fabXQ3 #NPMMF #NTH #NordPreciousMetals #Silver #SilverStocks #Mining #JuniorMining #Ontario #OTCQB #InvestorWebinar
129
📣 Two Days Out: FibroBiologics (NASDAQ: FBLG) Live Investor Webinar, Thursday, November 19 at 4:15 PM ET If you haven’t registered yet, now is the time. On Thursday, management will discuss FibroBiologics’ fibroblast-based pipeline and recent progress in intellectual property and preclinical research. It’s a direct chance to ask about clinical plans, pipeline priorities and the path forward. 🎯 Topics to hear about: The company’s clinical-stage pipeline in chronic disease Its degenerative disc disease program, which uses allogeneic, cartilage-forming cells designed to restore what the disc has lost Its oncology approach: fibroblasts engineered as tumor-homing delivery vehicles A patent portfolio of more than 270 issued and pending patents, including the newly granted European patent Indications spanning wound healing, multiple sclerosis, psoriasis, orthopedics and human longevity Register now so you can join the live presentation and Q&A. 🔗 Register here: redchip.news/4fchsh2 #FBLG #FibroBiologics #CellTherapy #Fibroblasts #RegenerativeMedicine #WoundHealing #Biotech #NasdaqStocks #InvestorWebinar #SmallCapInvesting
116
More than 100 million people over age 65 get the seasonal flu each year, and many of them need an alternative to the vaccine. Traws Pharma (Nasdaq: TRAW) is developing an oral medication to prevent seasonal flu, which the company says would be the first of its kind and which targets a $5 billion market. The company is led by an experienced drug developer and a former director of the CDC. The key catalyst for investors is Phase 2 clinical data, which is expected in the near term. Learn more: redchip.com/stocks/TRAW #TrawsPharma #TRAW #Nasdaq #Biotech #Influenza #FluSeason #FluPrevention #InfectiousDisease #ClinicalTrials #BiotechStocks #SmallCapStocks #MicroCap #RedChip
181
Cancer claims about 10 million lives a year, and an estimated 90% of those deaths come from metastatic cancer. TransCode Therapeutics (Nasdaq: $RNAZ), led by scientists from Harvard Medical School, is developing a treatment for metastatic cancer. In a Phase 1 trial, its lead drug candidate showed favorable safety and tolerability, and the disease stabilized in some patients. It is now in a Phase 2 trial in colorectal cancer, the next key step for the program. #TransCodeTherapeutics #RNAZ #Nasdaq #Biotech #Oncology #MetastaticCancer #ColorectalCancer #CancerResearch #ClinicalTrials #RNATherapeutics #BiotechStocks #SmallCapStocks #MicroCap #RedChip Learn more: redchip.com/stocks/RNAZ
198
BioVie (Nasdaq: $BIVI): Phase 2 Long COVID Data Identify Patient Groups That May Benefit Most From Bezisterim BioVie presented findings from its Phase 2 ADDRESS-LC trial at the 4th Long COVID International Conference in Nice, France. Exploratory analyses identified two biologically distinct patient groups with different responses to bezisterim. Patients with elevated inflammation showed statistically significant improvements in cognition, while those with low white blood cell levels showed promising effects on fatigue and post-exertional malaise. Bezisterim also reduced neuropeptide Y (NPY) levels by approximately 33% versus placebo, a statistically significant finding involving a biomarker added to the NIH's RECOVER prioritization list. BioVie says the results support a more targeted approach to future Long COVID trials. The study was fully funded by a $13.13 million U.S. Department of War award, and bezisterim's safety profile was comparable to placebo. Full press release: redchip.com/stocks/BIVI
1
182
Venu Holding Corporation (NYSE American: $VENU): Assets Surge 59% to $587.6 Million as Two New Amphitheaters Prepare to Open Venu Holding (NYSE American: VENU) reported Q3 2026 results as it prepares to bring two major entertainment venues online. Total assets climbed 59% from year-end 2025 to $587.6 million. Regent Bank Amphitheater in Oklahoma is scheduled to open on New Year's Eve, while Sunset Amphitheater McKinney in Texas is expected to be completed in Q1 2027. Cumulative Luxe FireSuite and Aikman Club sales have surpassed $300 million, with McKinney's Luxe FireSuites 95% sold ahead of opening. At Ford Amphitheater, average revenue per show rose nearly 10% to $609,000. VENU also closed a $60 million sale-leaseback to help fund McKinney's completion while retaining ownership of the amphitheater. With more than 110 event holds across its portfolio for 2027, management expects a meaningful increase in ticketing, food and beverage, and sponsorship revenue as the new venues begin operating. Full press release: redchip.news/4zsO4uy
153
Vector Science and Therapeutics (TSXV: $PAIN): Dr. James Andrews and Former HHS Secretary Tommy Thompson to Unveil Major Peptide-Related Medical Development November 18 Sports medicine pioneer Dr. James Andrews and Vector Chairman Tommy G. Thompson, former U.S. Secretary of Health and Human Services, will host a livestreamed briefing on November 18 at 11:00 a.m. CST (12:00 p.m. ET) to announce what the company describes as a major medical development involving peptides in the United States. Vector is advancing targeted drug delivery technologies and pharmaceutical-grade prescription peptides for sports medicine, regenerative medicine, pain management and wound care. Its portfolio includes advanced transdermal delivery, precision catheter systems and smart wound care technologies, with peptides manufactured under pharmaceutical quality standards. Learn more: redchip.news/4C3Q2nB
1
1
231
📣 Nord Precious Metals (OTCQB: $NPMMF, TSXV: NTH) Live Investor Webinar: Tuesday, November 24 at 4:15 PM ET Nord Precious Metals is advancing a district-scale silver portfolio in Ontario’s historic Cobalt-Gowganda camp, one of the world’s highest-grade primary silver regions. Its strategy has two tracks: a potential near-term path to silver production from historic tailings already at surface, and long-term exploration at the high-grade Castle East discovery. Mark your calendar to hear management outline both. 🔍 Why investors are watching: An updated NI 43-101 indicated resource of 2.814M ounces of silver grading 47.4 g/t at the Gowganda tailings project A historical inferred resource of 7.56M ounces of silver grading 8,582 g/t at Castle East Assets with more than 57 million ounces of historical silver production Engineering and permitting advancing under Ontario’s streamlined Mineral Recovery Permit framework A 560-metre surface gold trend that adds potential upside beyond silver Register now to reserve your spot for the live presentation and Q&A. 🔗 Register here: redchip.news/4fabXQ3 #NPMMF #NTH #NordPreciousMetals #Silver #SilverStocks #Mining #JuniorMining #Ontario #OTCQB #InvestorWebinar #RedChip
1
195
Nova Minerals Corp. (NYSE American: $NVA): Final Antimony Permits Secured as Company Advances Toward 2027 Pilot Production in Alaska Nova Minerals Corp. reported third-quarter 2026 results and continued progress at its Estelle Gold and Critical Minerals Project in Alaska. After the quarter ended, Nova received all final state approvals for its three-year pilot-scale antimony project, which covers mining, ore processing and refining. About 500 tons of processing and refining equipment has been delivered to Port MacKenzie, and early earthworks are underway. The antimony program is funded by a $43.4 million U.S. Department of War award, and Nova has received about $23.9 million of it so far. On the gold side, Nova completed an extensive 2026 drilling program and continues the technical work for its Gold Pre-Feasibility Study. CEO Christopher Gerteisen said the permits bring Nova a significant step closer to establishing a secure U.S. domestic antimony supply chain. Full press release: redchip.news/4kPZa8Y
1
294
Zeo Energy (Nasdaq: $ZEO): Energy Affordability Moves to Center Stage After 2026 Midterms in Zeo’s Core Markets Zeo Energy (Nasdaq: ZEO) reports that electricity affordability emerged as a major issue in its five core markets—Florida, Pennsylvania, Ohio, Texas and Virginia—following the November 3 midterm elections. Winning candidates from both parties emphasized expanding power generation and protecting households from rising electricity costs, including those associated with data center demand. Zeo sees these priorities supporting demand for residential solar while creating opportunities for its expansion into commercial energy generation and long-duration storage for data centers and other large power users. At the federal level, industry analysts see potential for an extension of solar tax credits in 2027, which could further support the sector. CEO Tim Bridgewater said the election results align with Zeo's strategy of helping homeowners control energy costs while providing power solutions for energy-intensive businesses. Full press release: redchip.com/stocks/ZEO
2
322
Greenwich LifeSciences (Nasdaq: $GLSI): CEO Interview Airs on RedChip’s Small Stocks, Big Money™ Show on Bloomberg TV and CNBC This Weekend Greenwich LifeSciences (Nasdaq: GLS) CEO Snehal Patel joins the RedChip Small Stocks, Big Money™ show to discuss GLSI-100. The immunotherapy is designed to prevent HER2-positive breast cancer from returning after surgery. In an earlier Phase IIb trial, GLSI-100 showed about an 80% reduction in recurrence. Patel discusses early observations from the company’s ongoing Phase III FLAMINGO-01 trial, which could support expanding the treatment to a broader patient population. He also covers the trial’s expansion across the U.S. and Europe, progress in commercial-scale manufacturing and upcoming interim analyses. The interview airs on Bloomberg TV Saturday, November 14, at 7:00 p.m. ET and on CNBC Sunday, November 15, at 11:30 a.m. ET. Watch the full interview: redchip.news/48j2CBH
3
543